Article
Pathology
Wenjiao Zhu, Wei Wang, Yuanping Shi, Bo Shen, Yan Li
Summary: Angiogenesis inhibitors, such as tyrosine kinase inhibitors (TKIs), are commonly used to treat oncologic disease. Surufatinib, a novel small-molecule multiple receptor TKI, has been approved for the treatment of pancreatic and extrapancreatic neuroendocrine tumors. However, it can cause thrombotic microangiopathy and nephrotic syndrome as complications.
Review
Urology & Nephrology
Qinghua Yin, Na Guo, Xueli Zhou, Huan Xu, Song Lei, Ping Fu, Hui Zhong
Summary: This case report and literature review highlight the first reported case of regorafenib-induced TMA and emphasize the rare but life-threatening complications of TKIs in cancer treatment.
Article
Oncology
Wentao Liu, Dianyun Ren, Wei Xiong, Xin Jin, Liang Zhu
Summary: Our study identified that NFAT1, when overexpressed in RCC, was associated with poor prognosis and could enhance tumor growth by increasing PD-L1 expression. Additionally, NFAT1 was found to be stabilized in sunitinib-resistant RCC through hyperactivation of the PI3K/AKT/GSK-3 beta signaling pathway. The downregulation of FBW7, which promotes NFAT1 degradation, was induced by FOXA1 and SETD2 in sunitinib-resistant RCC, contributing to immune response modulation. This study reveals a new role for the FBW7/NFAT1 axis in RCC response to TKIs and ICIs, suggesting NFAT1 as a potential therapeutic target for RCC treatment.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Takaya Ozeki, Michio Nagata, Takayuki Katsuno, Koji Inagaki, Kazunori Goto, Sawako Kato, Yoshinari Yasuda, Naotake Tsuboi, Shoichi Maruyama
Summary: This study analyzed the clinical implication of unclassified segmental lesions in Japanese adult patients with nephrotic syndrome compared to Columbia-classified FSGS. The results showed that unclassified segmental lesions may have equivalent clinical impact as Columbia classification of FSGS, with similar treatment responses and no significant difference in the decline of eGFR.
Article
Medicine, General & Internal
Da Woon Kim, Hakeong Jeon, Sungmi Kim, Wanhee Lee, Hyo Jin Kim, Harin Rhee, Sang Heon Song, Eun Young Seong
Summary: FSGS is a common primary glomerular disorder that can be caused by pembrolizumab, an immune checkpoint inhibitor used for advanced melanoma. This case study highlights the importance of monitoring renal function and considering kidney biopsy in patients treated with PD-1 inhibitors who develop renal injury or unexplained proteinuria. Treatment based on guidelines can lead to resolution of nephrotic syndrome in such cases.
Article
Oncology
Yan Sun, Liang Zhu, Pian Liu, Huan Zhang, Feng Guo, Xin Jin
Summary: In this study, researchers found that the upregulation of palmitoyl acyltransferase ZDHHC2 is associated with TKI resistance in ccRCC. ZDHHC2 mediates AGK S-palmitoylation to activate the PI3K-AKT-mTOR signaling pathway, which modulates sunitinib sensitivity. These findings suggest that targeting ZDHHC2 may improve the efficacy of sunitinib in treating ccRCC.
Article
Chemistry, Multidisciplinary
Wei Xiong, Bin Zhang, Haixin Yu, Liang Zhu, Lu Yi, Xin Jin
Summary: The study reveals that upregulated RRM2 in sunitinib-resistant RCC promotes resistance to TKIs, but the exact mechanism remains unclear. Additionally, RRM2 also impacts anti-tumor immune responses, and silencing RRM2 can enhance the efficacy of PD-1 blockade in renal cancer.
Article
Biochemistry & Molecular Biology
Eva Juengel, Pascal Schnalke, Jochen Rutz, Sebastian Maxeiner, Felix K. -H. Chun, Roman A. Blaheta
Summary: Axitinib significantly suppressed the growth of sunitinib-resistant HUVECs and induced cell cycle arrest at the G0/G1 phase. Both axitinib and sorafenib reduced HUVEC tube length and prevented wound closure in sunitinib-resistant HUVECs after six weeks of treatment, with sorafenib showing slightly better results.
Article
Oncology
Ondrej Fiala, Pavel Ostasov, Aneta Rozsypalova, Milan Hora, Ondrej Sorejs, Jan Sustr, Barbora Bendova, Ivan Travnicek, Jan Filipovsky, Jindrich Finek, Tomas Buchler
Summary: The retrospective study analyzed clinical data from 343 patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib or pazopanib, and found that the use of metformin was associated with significantly longer progression-free survival (PFS) and overall survival (OS) compared to non-users. The Cox multivariate analysis confirmed that metformin use remained a significant factor for both PFS and OS, indicating a favorable outcome for mRCC patients receiving sunitinib or pazopanib treatment.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, Nadine Houede, Brigitte Laguerre, Giuseppe Procopio, Stephanie Lheureux, R. Fischer, Sylvie Negrier, Alain Ravaud, Stephane Oudard, Bernard Escudier, Laurence Albiges, Camillo Porta
Summary: The study investigated the benefit of using other tyrosine kinase inhibitors (TKIs) or mTOR inhibitors for mRCC patients who did not respond well to first-line sunitinib treatment. The results showed minimal benefit in using further TKIs or mTOR inhibitors for these primary refractory patients.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Transplantation
Takehiko Kawaguchi, Toshiyuki Imasawa, Moritoshi Kadomura, Hiroshi Kitamura, Shoichi Maruyama, Takaya Ozeki, Ritsuko Katafuchi, Kazumasa Oka, Yoshitaka Isaka, Hitoshi Yokoyama, Hitoshi Sugiyama, Hiroshi Sato
Summary: In this study, the associations between different variants of FSGS and renal outcomes were comprehensively investigated. The results showed that the FSGS variants alone did not have significant impacts on renal outcome after 5 years. However, proteinuria remission (PR) could predict improved renal prognosis for any variant.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Pharmacology & Pharmacy
Marieke Van Daele, Laura E. Kilpatrick, Jeanette Woolard, Stephen J. Hill
Summary: Vascular endothelial growth factor (VEGF) is crucial for angiogenesis and vascular endothelial cell functions. The study developed a ligand-binding assay to monitor the binding affinity and kinetics of different tyrosine kinase inhibitors (TKIs) to VEGF receptor 2 (VEGFR2). The results showed that compounds inhibiting the binding of a fluorescent analogue of sunitinib (sunitinib-red) also attenuated VEGFR2-mediated signaling, suggesting potential cardiovascular liabilities.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Urology & Nephrology
Ke Sun, Qionghong Xie, Chuan-Ming Hao
Summary: This study focuses on the potential sources and mechanism of podocyte supplementation in FSGS. Parietal epithelial cells (PECs) have gained attention for their role in the progression of FSGS, as both influencing factors in glomerulosclerosis lesions and their repair abilities are being debated. Other resident glomerular cells are also significant in the progression of the disease.
Article
Multidisciplinary Sciences
Takaya Ozeki, Shoichi Maruyama, Toshiyuki Imasawa, Takehiko Kawaguchi, Hiroshi Kitamura, Moritoshi Kadomura, Ritsuko Katafuchi, Kazumasa Oka, Hitoshi Yokoyama, Hitoshi Sugiyama, Hiroshi Sato
Summary: Research found that primary FSGS patients aged 18-64 years had a lower rate of NS compared to other age groups in the Japanese registry database. FSGS showed distinct clinical features different from MCD in primary nephrotic cases.
SCIENTIFIC REPORTS
(2021)
Article
Chemistry, Multidisciplinary
Qiong-Dan Hu, Hong-Lian Wang, Jian Liu, Tao He, Rui-Zhi Tan, Qiong Zhang, Hong-Wei Su, Fahsai Kantawong, Hui-Yao Lan, Li Wang
Summary: Btg2 plays a pathogenic role in FSGS by promoting podocyte injury through a Smad3-dependent epithelial-mesenchymal transition pathway.
Meeting Abstract
Oncology
G. Prado Vazquez, A. Gamez Pozo, L. Trilla Fuertes, A. Zapater Moros, E. Lopez Camacho, R. Lopez Vacas, M. Diaz Almiron, P. Zamora, J. A. Fresno Vara, E. Espinosa
ANNALS OF ONCOLOGY
(2020)
Article
Oncology
Lucia Trilla-Fuertes, Angelo Gamez-Pozo, Elena Lopez-Camacho, Guillermo Prado-Vazquez, Andrea Zapater-Moros, Rocio Lopez-Vacas, Jorge M. Arevalillo, Mariana Diaz-Almiron, Hilario Navarro, Paloma Main, Enrique Espinosa, Pilar Zamora, Juan Angel Fresno Vara
Article
Multidisciplinary Sciences
Lucia Trilla-Fuertes, Angelo Gamez-Pozo, Jorge M. Arevalillo, Rocio Lopez-Vacas, Elena Lopez-Camacho, Guillermo Prado-Vazquez, Andrea Zapater-Moros, Mariana Diaz-Almiron, Maria Ferrer-Gomez, Hilario Navarro, Paolo Nanni, Pilar Zamora, Enrique Espinosa, Paloma Main, Juan Angel Fresno Vara
Article
Oncology
L. Gutierrez-Sainz, V. Martinez-Marin, D. Vinal, D. Martinez-Perez, J. Pedregosa, J. A. Garcia-Cuesta, J. Villamayor, P. Zamora, A. Pinto, A. Redondo, B. Castelo, P. Cruz, O. Higuera, A. Custodio, A. Gallego, D. Sanchez-Cabrero, J. de Castro-Carpeno, E. Espinosa, J. Feliu
Summary: The incidence of VTE in cancer patients receiving immunotherapy is similar to that in cancer patients treated with systemic therapies. VTE occurrence is not correlated with the prognosis, and further prospective studies are needed to draw definitive conclusions.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Alejandro Gallego, Beatriz Martinez, Ismael Ghanem, Jose Miguel Cantero, Enrique Espinosa, Beatriz Castelo, Pilar Zamora, Leticia Ruiz-Gimenez, Andres Redondo, Jaime Feliu
Summary: Long-term cancer survivors (LTCS) in the Spanish population were studied through an observational descriptive study, revealing significant socioeconomic, labor, sexual, health, and psychological problems in this group, especially among older survivors. It is important to address common concerns of LTCS, which may persist even years after cancer treatment, and may require expert attention.
JOURNAL OF CANCER SURVIVORSHIP
(2021)
Article
Biochemical Research Methods
Silvia Garcia-Adrian, Lucia Trilla-Fuertes, Angelo Gamez-Pozo, Cristina Chiva, Rocio Lopez-Vacas, Elena Lopez-Camacho, Andrea Zapater-Moros, Maria Lumbreras-Herrera, David Hardisson, Laura Yebenes, Pilar Zamora, Eduard Sabido, Juan Angel Fresno Vara, Enrique Espinosa
Summary: The study analyzed the proteomes of 125 patients with triple negative breast cancer and identified two molecular groups with differences in biological processes, which may help in designing new therapeutic strategies in the future.
Article
Pharmacology & Pharmacy
Alejandro Velasco-Ruiz, Rocio Nunez-Torres, Guillermo Pita, Hans Wildiers, Diether Lambrechts, Sigrid Hatse, Danielle Delombaerde, Thomas Van Brussel, M. Rosario Alonso, Nuria Alvarez, Belen Herraez, Christof Vulsteke, Pilar Zamora, Teresa Lopez-Fernandez, Anna Gonzalez-Neira
Summary: A novel gene variant, rs62134260 located upstream of POLRMT, was identified through a two-stage genome-wide association study as a potential predictor of anthracycline-induced cardiotoxicity in breast cancer patients. This variant was found to regulate the expression of POLRMT, impacting mitochondrial gene expression in heart tissue and potentially leading to impaired mitochondrial maintenance in cardiomyocytes under stress conditions like epirubicin treatment. This discovery suggests a new molecular mechanism involved in AIC development and may enhance our ability to predict at-risk patients.
Article
Medicine, Research & Experimental
Elena Lopez-Camacho, Lucia Trilla-Fuertes, Angelo Gamez-Pozo, Irene Dapia, Rocio Lopez-Vacas, Andrea Zapater-Moros, Maria Isabel Lumbreras-Herrera, Pedro Arias, Pilar Zamora, Juan Angel Fresno Vara, Enrique Espinosa
Summary: The combination of antimetabolic drugs with chemotherapy drugs showed synergistic effects on triple-negative breast cancer cells, leading to potential therapeutic strategies that reduce chemotherapy drug doses or enhance their efficacy.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Serena Di Cosimo, Jose Manuel Perez-Garcia, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz Borrego, Joaquin Gavila, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marme, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martinez-De Duenas, Vicente Caranana, Kepa Amillano, Leonardo Mina, Andrea Malfettone, Javier Cortes, Antonio Llombart-Cussac
Summary: This study provides a comprehensive summary of the safety and tolerability of the combination of endocrine therapy and palbociclib in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. The results confirmed the favorable safety profile of palbociclib regimens with occasional occurrence of venous thromboembolism and interstitial lung disease/pneumonitis, which can be effectively managed without compromising efficacy.
Article
Cardiac & Cardiovascular Systems
Juan Caro-Codon, Teresa Lopez-Fernandez, Carlos Alvarez-Ortega, Pilar Zamora Aunon, Isabel Rodriguez Rodriguez, Pilar Gomez Prieto, Antonio Buno Soto, Miguel Canales Albendea, Ainara Albaladejo, Guiomar Mediavilla, Jaime Feliu Batlle, Olaia Rodriguez Fraga, Amparo Martinez Monzonis, Jose Gonzalez-Costello, Jose Maria Serrano Antolin, Rosalia Cadenas Chamorro, Jose R. Gonzalez-Juanatey, Jose Lopez-Sendon
Summary: This study aimed to investigate the actual usefulness of cardiovascular risk factor assessment in the prognostic evaluation of cancer patients treated with cardiotoxic treatment. The results showed a significant prevalence of cardiovascular risk factors at baseline and during follow-up. The use of Systemic Coronary Risk Estimation (SCORE) for baseline risk assessment predicted severe cardiotoxicity and all-cause mortality. Therefore, it should be considered in the evaluation of cancer patients.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2022)
Meeting Abstract
Oncology
J. M. Oliver-Goldaracena, J. I. Sanchez Mendez, C. Marti, E. York, P. Zamora, V. Cordoba Chicote, M. J. Roca Navarro, D. Garrido Alonso, Y. Navarro Monforte
Meeting Abstract
Oncology
Luis Manso, Patricia Villagrasa, Nuria Chic, Begona Bermejo, Juan Miguel Cejalvo, Yann Izarzugaza, Blanca Cantos, Salvador Blanch, Mireia Margeli, Jose Luis Alonso, Alejandro Martinez, Rafael Villanueva, Juan Antonio Guerra, Raquel Andres, Pilar Zamora, Esteban Nogales, Manel Juan, Blanca Gonzalez, Rita Laeufle, Gerard Nuovo, Grey Wilkinson, Matt Coffey, Azucena Gonzalez, Debora Martinez, Laia Pare, Fernando Salvador, Xavier Gonzalez, Aleix Prat, Joaquin Gavila
Meeting Abstract
Oncology
Jose Manuel Perez-Garcia, Antonio Llombart-Cussac, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz Borrego, Joaquin Gavila, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marme, Serena Di Cosimo, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martinez-De Duenas, Vicente Caranana, Kepa Amillano, Andrea Malfettone, Javier Cortes
Article
Pharmacology & Pharmacy
M. Garcia-Trevijano Cabetas, P. Lucena Martinez, I. Jimenez Nacher, M. Diaz Almiron, P. Zamora Aunon, A. Herrero Ambrosio
Summary: This study evaluated the real-world effectiveness and toxicities of palbociclib and ribociclib in hormone receptor-positive metastatic breast cancer patients. Neutropenia was the most common adverse event, managed with regimen changes like dose adjustments and treatment interruptions. While there were no statistically significant differences in progression-free survival rates, both drugs showed favorable outcomes similar to phase III trials. Further research is needed to confirm the impact of regimen changes on effectiveness.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
(2021)
Meeting Abstract
Oncology
Luis Manso, Patricia Villagrasa, Nuria Chic, Begona Bermejo, Juan Cejalvo, Yann Izarzugaza, Blanca Cantos, Salvador Blanch, Mireia Margeli, Jose Alonso, Alejandro Martinez, Rafael Villanueva, Juan Guerra, Raquel Andres, Pilar Zamora, Esteban Nogales, Manel Juan, Blanca Gonzalez-Farre, Thomas Heineman, Gerard Nuovo, Grey Wilkinson, Matt Coffey, Azucena Gonzalez, Debora Martinez, Laia Pare, Fernando Salvador, Xavier Gonzalez, Aleix Prat, Joaquin Gavila
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
